logo
1930s 'Dragon Man' Finally Gives Elusive Ancient Human Species a Face

1930s 'Dragon Man' Finally Gives Elusive Ancient Human Species a Face

Yahoo19-06-2025
A 146,000-year-old skull known as the 'dragon man', thought to be the sole representative of an ancient human species, actually belongs to a larger group of our extinct relatives, the Denisovans, two new papers claim.
It's the first skull we have from that group, and it was right under our noses for years.
Paleontologist Qiaomei Fu, from the Chinese Academy of Sciences, specializes in early modern human settlement in Asia. She led two new studies that reveal the mistaken identity of this skull, using proteins and mitochondrial DNA her team found preserved in the fossil.
The 'dragon man' skull was discovered in the 1930s by a construction worker who was erecting a bridge over the Songhua River in Harbin, China, while the region was under Japanese occupation. The province is known as Longjiang, meaning 'dragon river', hence the skull's nickname.
The bridge builder kept the specimen to himself, hiding it at the bottom of a well. It was only when his family donated it to Hebei GEO University in 2018 that research on this unique find began.
In 2021, the skull was declared a new species of ancient human, Homo longi, but Fu's research rebukes this categorization. That initial description was based on comparative morphology, where paleontologists look at the physical appearance of different fossils to decide where they sit in the family tree.
But morphology can mislead: members of the same species often look very different depending on lifestyle and environment.
Trying to extract fragile molecular evidence from fossils – especially DNA to compare genetic similarity – is often a destructive and patchy task with no guarantee of payoff, but in this case, Fu and her colleagues had astonishing success.
The team was able to retrieve proteins from the skull's petrous bone – one of the densest in the body. They also got hold of mitochondrial DNA (which contains less detail than the DNA stored in a cell nucleus, but is still very useful) from plaque on the dragon man's teeth.
Dental plaque is not widely considered a source of DNA, perhaps because it's the result of a biofilm rather than a direct part of the host's body.
"The finding that the human DNA of the Harbin specimen is better preserved in the dental calculus than in dense bones, including the petrous bone, suggests that dental calculus may be a valuable source for investigating DNA in Middle Pleistocene hominins," Fu and her team write.
These molecules suggest the man is not as unique from other ancient humans as the skull's physical appearance suggests. That's partly because we don't actually have any other complete Denisovan skulls to refer to: until now, they were known only from teeth, one skull fragment, bits of jaw, and a few other body parts.
But the dragon man's mitochondrial DNA reveals a species-level relationship to at least five other Denisovan individuals known from fossil remains found in Siberia. And among the amino acid fragments of 95 proteins found within his skull, four were unmistakably Denisovan, and three were direct matches.
There are limitations to these sampling methods that leave some room for doubt, but Fu and team's findings are enough to place him among the Denisovans for now.
We may have lost a species of ancient human – farewell Homo longi, it was good while it lasted – but it seems we've gained the first ever complete Denisovan skull. Which is pretty wild, given that this missing puzzle piece, a frustrating gap in the paleoanthropologists' catalogue, has actually been in the hands of modern humans for nearly 100 years.
As they say, it's always in the last place you look.
The research is published in Science and Cell.
How Long Would Humans Survive Once The Last Baby Is Born?
Humans Have Smoked Meat For Almost 2 Million Years, Study Suggests
'As If Time Froze': France's Deepest Shipwreck Stuns Archaeologists
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China
ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China

Yahoo

timean hour ago

  • Yahoo

ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China

Partial responses observed in 80% of squamous NSCLC front-line patients and in 46% of non-squamous NSCLC front-line patients Safety profile supports further clinical development, with no dose-limiting toxicities observed in patients with front-line NSCLC ImmuneOnco expects to present updated safety and efficacy data at a future medical conference DALLAS and SHANGHAI, July 31, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, 'Instil') noted that ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: ('ImmuneOnco'), today announced preliminary safety and efficacy data from the Phase 2 open-label, multicenter study of IMM2510/AXN-2510 ('2510) in combination with chemotherapy for front-line patients with advanced non-small cell lung cancer (NSCLC) conducted in China by ImmuneOnco. As of July 1, 2025, 33 patients were dosed at 10 mg/kg, with 21 patients having at least one tumor assessment (efficacy evaluable). Partial responses were observed in 62% of efficacy evaluable patients, comprising partial responses in 80% (8/10) of patients with squamous NSCLC and 46% (5/11) of patients with non-squamous NSCLC. The majority of efficacy evaluable patients had only one tumor assessment at data cut-off. ImmuneOnco expects to present safety and efficacy data in the '2510 chemotherapy combination trial in front-line NSCLC at a future medical conference. The '2510 safety profile supports further clinical development, with no dose-limiting toxicities observed in the 33 safety evaluable patients. In these patients, there were no treatment-related adverse events (TRAE) leading to dose reduction or death, and only one TRAE leading to drug discontinuation. The most common Grade 3+ TRAEs were hematologic, with uncommon clinical sequelae. Adverse events typically associated with VEGF inhibition (e.g., hypertension, proteinuria, hemoptysis) and immune-related adverse events were uncommon and generally low-grade, and infusion-related reactions were nearly all low-grade. ''2510 has demonstrated early but compelling activity in front-line NSCLC patients,' said Professor Caicun Zhou, M.D., Ph.D., director of the Department of Oncology at Shanghai East Hospital, Tongji University, and lead investigator on the study of '2510 in 1L NSCLC. 'The PD-(L)1xVEGF bispecific class has the potential to become the new standard of care for front-line NSCLC, and I look forward to the generation of additional data with '2510 in this setting.' Dr. Tian Wenzhi, CEO of ImmuneOnco, said 'We are delighted to witness the progress of '2510 in front-line non-small cell lung cancer (NSCLC). This data paves the way for its advancement into Phase 3 clinical studies and provides valuable insights to support further research across multiple indications.' 'We are pleased with the preliminary clinical results of the combination of '2510 with chemotherapy in patients with front-line NSCLC, which suggest the potential for best-in-class efficacy in the promising PD-(L)1xVEGF bispecific antibody class,' said Bronson Crouch, CEO of Instil. 'We look forward to further public updates from ImmuneOnco on these data, as well as the initiation of our previously announced US phase 1 clinical trial before the end of this year.' About IMM2510/AXN-2510IMM2510/AXN-2510 is a PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumors. IMM2510/AXN-2510 is differentiated from other PD-(L)1xVEGF bispecific antibodies by its VEGF trap, which binds multiple VEGF receptor ligands beyond VEGF-A, a bispecific structure which leverages PD-L1 as an anchor in the tumor microenvironment (TME), and enhanced antibody-dependent cellular cytotoxicity (ADCC) to direct killing of PD-L1-positive tumor cells. About ImmuneOncoImmuneOnco is a clinical-stage biotech company focused on discovery and development of biologics to treat cancers, autoimmune diseases and metabolic diseases. With 10+ assets all originated in-house and the most advanced asset in phase III right now, ImmuneOnco is pursuing innovative therapies to improve patients' health. For more information visit About Instil BioInstil Bio is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. Instil's lead asset, AXN-2510, is a novel and differentiated PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumors. For more information, visit Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'anticipates,' 'believes,' 'expects,' 'future,' 'intends,' 'may,' 'plans,' 'potential,' 'targets' and 'will' or similar expressions are intended to identify forward-looking statements. Forward-looking statements include express or implied statements regarding our expectations with respect to the therapeutic potential, safety and efficacy profile, and clinical development of IMM2510/AXN-2510, including timing of initiation of a clinical trial in the United States, additional clinical trials and expansion into additional indications, the generation and presentation of clinical data from clinical trials, and other statements that are not historical fact. Forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements, including risks and uncertainties associated with the costly and time-consuming drug product development process and the uncertainty of clinical success; the risks inherent in relying on collaborators and other third parties, including for generating clinical data, and the ability to rely on any such data from clinical trials in China in regulatory filings submitted to regulatory authorities outside of China; the risks and uncertainties related to successfully making regulatory submissions and initiating, enrolling, completing and reporting data from clinical trials, as well as the risks that results obtained in any clinical trials to date, including preliminary clinical data, may not be indicative of final results in such clinical trials or results obtained in ongoing or future trials and that product candidates may otherwise not be effective treatments in their planned indications; risks related to macroeconomic conditions, including as a result of international conflicts and U.S.-China trade and political tensions, as well as interest rates, inflation, tariffs and other factors, which could materially and adversely affect our business and operations and those of our collaborators; the risks and uncertainties associated with the time-consuming and uncertain regulatory approval process; and other risks and uncertainties affecting Instil's plans and development programs, including those discussed in the section titled 'Risk Factors' in Instil's Quarterly Report on Form 10-Q, for the quarter ended March 31, 2025 filed with the SEC, as well as Instil's other filings with the SEC. Additional information will be made available in other filings that Instil makes from time to time with the SEC. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as the date hereof, and Instil disclaims any obligation to update these statements except as may be required by law. Contacts:Investor Relations:1-972-499-3350investorrelations@

The U.S. invented these technologies. Then China dominated them.
The U.S. invented these technologies. Then China dominated them.

Washington Post

timean hour ago

  • Washington Post

The U.S. invented these technologies. Then China dominated them.

China calls them the 'new three' — electric vehicles, solar panels and lithium-ion batteries — a set of technologies to replace the country's previous export focus on furniture, clothing and household appliances. And those technologies have something in common: They were all invented in the United States. Since the early 2000s, a suite of government incentives and policies has swept China to the forefront of the market for EVs, solar panels and batteries. But most of the world's clean technologies were initially invented in the U.S. In an alternate reality, the U.S. could have become the world's leader.

'Communities' of strange, extreme life seen for first time in deep ocean
'Communities' of strange, extreme life seen for first time in deep ocean

Yahoo

timean hour ago

  • Yahoo

'Communities' of strange, extreme life seen for first time in deep ocean

Beds of clams, mats of bacteria that look like ice and fields of tube worms - these are just some examples of the strange, extreme life that an expedition to the deepest parts of the ocean has observed, filmed and photographed. Diving in a human-occupied submersible to ocean trenches in the northwest Pacific Ocean, a Chinese-led research team captured pictures of life at depths of more than 9km (5.6miles). The deepest marine life filmed before this expedition was at 8,336m - a snailfish that was filmed swimming in a deep ocean trench off the coast of Japan in 2023. These new observations are published in the journal Nature. Although it was accepted among marine scientists that there would be life at these depths, scientists on this mission say the abundance of animals they saw from the windows of their submersible was "amazing". The scientific expedition covered more than 2,500km - exploring trenches at depths ranging from 5,800 to 9,533m. Researchers travelled in a submersible vehicle called Fendouzhe, which can operate at depths of more than 10km for several hours at a time. The team, led by researchers from the Chinese Academy of Sciences' Institute of Deep Sea Science and Engineering, discovered what they describe as "thriving communities" of creatures. "It's exciting - especially for a deep sea scientist - to go to a place that human beings have not explored," one of the lead researchers, Dr Xiaotong Peng, told BBC News. "It's a great opportunity to discover new things. And what we saw was quite amazing." Scientists photographed and filmed what looked like fields of marine life - dominated by various different types of tube worm and mollusc. These animals live in the pitch dark and under vast pressure. With no sunlight, life at these depths is fuelled by chemicals that seep out of the ocean floor. Hydrogen sulfide and methane seep out of faults - or cracks - in the Earth's crust. The scientists say they have recorded species never seen before. In future studies, they hope to work out how the bodies of these so called "chemosynthetic" or chemical-fuelled creatures convert these chemicals into energy. "They must [also] have a trick to adapt to life in super high pressure," added Dr Megran Du, also from China's Institute of Deep Sea Science and Engineering. "That's another question we need to answer." The findings challenge "long-standing assumptions" about life's potential at such extreme depths and pressures. They also suggest that these communities of animals, rather than extreme rarities, are actually widespread. Prof Andrew Sweetman, a senior scientist from the Scottish Association for marine science told BBC News that the discovery showed that whole "ecosystems driven by methane may exist in the deepest parts of the ocean". And how did it feel, for a scientist, to descend to such extreme, pitch-black depths? Dr Du told BBC News: "Some people might find it frightening, but I always encourage my students - look through the window at the bottom of the sea," she said. "You will be inspired." Solve the daily Crossword

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store